2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).
about
MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancerClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerThe FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival timeClinical Translation of Nanomedicine.Role of cytoreductive surgery in recurrent ovarian cancer.Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocolGlobal gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroidsActivity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancerEffect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer.Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer PatientsThe COMET Handbook: version 1.0.Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy.Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.Ovarian metastases resection from extragenital primary sites: outcome and prognostic factor analysis of 147 patients.LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009Clinical course of patients treated for advanced ovarian carcinoma without surgical interventionEnhancing chemotherapy response with Bmi-1 silencing in ovarian cancerPotential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer.A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancerA randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group StudyClinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.Thoracic metastasis in advanced ovarian cancer: comparison between computed tomography and video-assisted thoracic surgery.Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer.Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinomaCross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France.A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIGDoublet chemotherapy in the elderly patient with ovarian cancer.Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.Are there candidates for high-dose chemotherapy in ovarian carcinoma?
P2860
Q24632636-8D4711C9-48C1-49B0-8B88-C21959772B43Q27024235-A3E8F968-8FDF-4902-8CCA-BF4628D40B42Q27853172-A97ABA18-F475-463C-82C8-667949E0F13AQ28536347-356E23D8-849D-42CD-AEAB-17210066C252Q30355939-9C79A416-23D0-4F47-BAFE-464CAC042825Q30378801-5591B0C5-BC2E-4CAB-B50A-E552909EEB37Q30436714-11CE01CC-910B-465F-8AD4-7BA347E9D14EQ33311401-27BDAD0D-7E24-4232-8681-F44D00C498EFQ33321330-A743798D-44F2-4576-BF26-60480775009BQ33365433-97E772C7-EDAA-4414-8555-7E30AA4F8D0FQ33380181-A98E1A0E-F78B-450F-ABC6-FA28D1B0E359Q33393909-C17721B5-3525-49CF-B049-309DEAF2142BQ33648465-6FE5787A-7347-4E43-AC75-7765618659D1Q33776904-93D08AE9-D271-4269-8C1E-0789E274DAB2Q33801643-FB03B821-DA36-49E0-9161-48EF8B698E8EQ33838805-C622135B-26A4-4235-AF90-AEC3DCF9B61DQ33877196-D1FC6F4D-EDA3-4A1C-AE20-B0B3C5EFC6FEQ34115941-7036083A-D4DA-4CCF-8E4D-17656225DB82Q34300629-796ED3C4-3ADF-481E-BC52-CB09D7B43C7DQ34324630-477F086D-A2D9-4CAB-B3F1-ABD17AA0C42AQ34360216-BA492579-2F2E-4AA0-B897-DAF1ED87B698Q34389383-020F0F8D-A8A5-44AB-BF9F-DAD4B0C028CEQ34390396-DC4ED8F5-184A-48EE-8A3E-C685D1E29F16Q34576852-3DACCCF9-4C62-4761-BF58-412F81FEA63FQ34704011-113AC980-76B8-4FE8-89CF-3421176E6D5FQ34833628-01B1F89C-FE9F-4A94-832D-4FB58571ADA3Q34967545-318AD519-1F43-4650-9395-9988E0170B0DQ35033234-A43EF4A1-8F3A-4173-80FD-04177F6B6125Q35575176-527C933F-1326-4E8B-8638-A4D90801F085Q35663648-5222E7B4-83D2-4476-9FAA-83F70DB5209FQ35666119-DA343F61-3639-445A-AFD0-FD4D80165CC5Q35967152-96B850AC-1D9B-4DFB-B14A-704F66F84A63Q36004735-2700DB0C-0482-497D-A14F-8AB9FAF96991Q36037099-53DC1C8D-0A73-454F-89C3-0E0E8CB957BAQ36239919-8CCABB89-9024-46C3-BDD8-66460DD52FF7Q36347386-BB7B2A40-39BB-4553-81E8-2D5F4D7E70AEQ36405668-7D1F58DB-16AF-4B14-BFE2-0978AC7D3017Q36433053-2D28F5BE-A12A-4910-A818-AFE4C571DF94Q36444374-16E2A79F-0632-46CF-8FBD-4B6AB2C18C02Q36468856-3FD6D9B0-A3AA-48A6-9393-E031DB4F812C
P2860
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
2004 consensus statements on t ...... s Conference (GCIG OCCC 2004).
@ast
2004 consensus statements on t ...... s Conference (GCIG OCCC 2004).
@en
type
label
2004 consensus statements on t ...... s Conference (GCIG OCCC 2004).
@ast
2004 consensus statements on t ...... s Conference (GCIG OCCC 2004).
@en
prefLabel
2004 consensus statements on t ...... s Conference (GCIG OCCC 2004).
@ast
2004 consensus statements on t ...... s Conference (GCIG OCCC 2004).
@en
P2093
P356
P1433
P1476
2004 consensus statements on t ...... s Conference (GCIG OCCC 2004).
@en
P2093
A Cervantes
D Provencher
P304
viii7-viii12
P356
10.1093/ANNONC/MDI961
P478
16 Suppl 8
P577
2005-01-01T00:00:00Z